Background: The diagnostic criteria of the metabolic syndrome (MS) have been applied in studies of obese adults to estimate the metabolic risk-associated with obesity, even though no general consensus exists concerning its definition and clinical value. We reviewed the current literature on the MS, focusing on those studies that used the MS diagnostic criteria to analyze children, and we observed extreme heterogeneity for the sets of variables and cutoff values chosen. Objectives: To discuss concerns regarding the use of the existing definition of the MS (as defined in adults) in children and adolescents, analyzing the scientific evidence needed to detect a clustering of cardiovascular risk-factors. Finally, we propose a new methodological approach for estimating metabolic risk-factor clustering in children and adolescents. Results: Major concerns were the lack of information on the background derived from a child's family and personal history; the lack of consensus on insulin levels, lipid parameters, markers of inflammation or steato-hepatitis; the lack of an additive relevant effect of the MS definition to obesity per se. We propose the adoption of 10 evidence-based items from which to quantify metabolic risk-factor clustering, collected in a multilevel Metabolic Individual Risk-factor And CLustering Estimation (MIRACLE) approach, and thus avoiding the use of the current MS term in children. Conclusion: Pediatricians should consider a novel and specific approach to assessing children/adolescents and should not simply derive or adapt definitions from adults. Evaluation of insulin and lipid levels should be included only when specific references for the relation of age, gender, pubertal status and ethnic origin to health risk become available. This new approach could be useful for improving the overall quality of patient evaluation and for optimizing the use of the limited resources available facing to the obesity epidemic.
Introduction
Since its inception in 1988, 1 the diagnostic criteria of the metabolic syndrome (MS) have been applied in several studies in obese adults to estimate the metabolic risk associated with obesity. [2] [3] [4] The MS was first defined as a combination of several metabolic risk-factors for cardiovascular disease (CVD) in one individual, including obesity, insulin resistance, glucose intolerance, hypertension and a characteristic dyslipidemia. 5 No general consensus exists concerning its definition, and in fact three definitions have been proposed in adults, by the World Health Organization (WHO), 6 the European Group for the Study of Insulin
Resistance/International Diabetes Federation (EGIR/IDF) [7] [8] and the National Cholesterol Education Program, Adult Treatment Panel III (ATP III). 9 Moreover, recent seminal papers [10] [11] [12] [13] [14] pointed out several concerns about the definition of the MS, among them that 'too much critically important information is missing to warrant its designation as a syndrome'. 12 Nonetheless, the three proposed definitions have been used in several studies carried out in pediatric populations, which reported high-prevalence of the MS in obese children and adolescents. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] The results of these studies varied according to the selected diagnostic criteria used, as established by a recent comparison study. 34 Moreover, in an evaluation of the different prevalence yields using different definition, Goodman et al. 35 found that ATP III definition identified half as many children and adolescents as having MS as did WHO definition in the same population. Thus, pediatricians are faced with the dilemma of whether to use this simple diagnostic tool to identify among the huge number of obese children those with high risk for co-morbidity, despite the wide criticism it has received. 12 The parameters of the MS develop in stages, according to age-related changes in obesity, so the full syndrome cannot generally be expressed at an early age. 36 Moreover, it is fundamental to take into account that in children and adolescents, the pathophysiological basis and characteristics of the MS are also influenced by growth and puberty, 36, 37 and not only by gender, ethnicity and body composition as they are in adults. The available literature has focused on the assessment of the MS in overweight and obese children; however, we suspect that a clustering of risk-factors can also be observed in normal-weight children and adolescents, 18, 22 as already shown in adults. [38] [39] [40] Therefore, the adoption of the current definitions of the MS, which have been developed for obese adults, should be taken with extreme caution in children and adolescents, as questioned clearly in very recent reports. 41, 42 The aims of this review are to discuss the main concerns regarding the use of the existing definition of the MS in children and adolescents, in addition to analyzing the scientific evidence needed to detect a clustering of cardiovascular risk-factors. Finally, we propose a new methodological approach for estimating metabolic risk-factor clustering in children and adolescents.
Actual features
We reviewed the relevant literature, focusing on those studies that defined and/or used the MS diagnostic criteria in children and adolescents. In Table 1 we present 15 papers, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] all of which used different sets of variables, number of criteria and cutoff points to define the risk-factors associated with the MS. [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] The main differences concern the techniques used to estimate adiposity (body mass index (BMI) and/or waist circumference (WC)), and the variable(s) chosen to evaluate glucose metabolism (fasting glucose, 
Critical points
The main concern for pediatricians is that none of the existing definitions of the MS is considered to be ideal. Table 2 outlines the major and minor concerns for the adoption of the adult MS diagnostic criteria in children and adolescents, mainly based on the supposed (or known) differences between obese children and obese adults.
Major concerns
The first major concern is related to the lack of an additive relevant effect of the MS to the risk of obesity. To verify how and which risk-factors are able to drive obesity to overt comorbidity, at least one (or more) long-term longitudinal study is needed, starting at a very early age and continuing until middle-aged or even elderly adults. This survey should be conducted on a large cohort of subjects, of both genders and different races, with a standardized variety of information (including family history, birth data, lifestyle information and body composition assessment over time, in addition to measurement of hormonal and metabolic parameters). Such a long-term study is useful in adults, but is mandatory in children for whom the clinical evidence of obesity-related morbidities often implies a long-term followup. Looking at the current pediatric literature on the MS, it is difficult to find long-term epidemiological studies that have all the required information, and the maximum duration of follow-up is not long enough. 61, 62 Only Rodriguez-Moran and co-workers 25 looked at the genetic background derived from the children's family history (i.e., phenotype and genotype). Knowledge of the presence of obesity-related diseases in the family is as important for the estimation of cardiovascular risk as the evidence of metabolic abnormalities. 42 It is difficult for a pediatrician to comprehend how similar risk estimation can be made for obese children coming from families with or without cases of diabetes mellitus type 2 (DM2), dyslipidemia, hypertension or early-onset CVD. This information is fundamental, as well as the presence of maternal obesity and/or gestational diabetes, which have been shown to increase the risk of obesity persistence and co-morbidity later in life. 26 Furthermore, the pediatrician does not underestimate the additional metabolic risk owing to a subject's birth-weight status (i.e., small for gestation age in particular).
63-65
The main difference among current adult definitions of the MS is in relation to insulin resistance evaluation. There is a general consensus on the importance of insulin resistance in the MS, but the ATP III and EGIR/IDF definitions estimate glucose metabolism only by means of fasting serum glucose, whereas the WHO criteria recognize any measure irrespective of insulin resistance. [6] [7] [8] [9] Studies on glucose metabolism in children and adolescents have shown that fasting hyperinsulinemia may be a precursor of impaired glucose tolerance and DM2, and that the detection of impaired fasting glucose might be linked to DM2 onset. [66] [67] [68] Therefore, a pediatrician should avoid using a marker like impaired fasting glucose, which is probably a late indicator of glucose homeostasis derangement, preferring the use of Metabolic risk-factor clustering estimation in children P Brambilla et al fasting insulin level as an early detector of a long-term risk-factor.
No other hormone levels or emerging biomarkers (e.g. leptin, adiponectin, ghrelin, other adipokines, free fatty acids or apolipoproteins) are included in any diagnostic criteria of the MS, even though they have been proposed as tools that provide valuable complementary information to that obtained from traditional biomarkers. 30, 69, 70 This is a concern which is also true for adults, and not just for obese children.
Pediatricians might find it surprising that classifications of the MS exclude data on the subject's puberty status and timing, despite this being known to influence markedly adipose tissue deposition, lipids and glucose metabolism homeostasis. 66, 71, 72 A metabolic derangement occurring during puberty could have a deep impact on health risk for obese subjects. 66 The possibility of using a definition based on insulin levels implies the availability of age/gender/race/ pubertal status-specific reference values. However, such insulin references are in fact lacking, and need to be derived from a large pediatric consensus. 59, 69 Published papers concerning the MS in children and adolescents reported a high prevalence, ranging up to 50% of the obese patients studied. 18, 19, 22, 24, 27, 29 This figure is definitely alarming, but we know that the prevalence recorded strongly depends on the definition chosen, with the estimate being much higher if insulin is part of the definition. 34 Regardless of insulin, a low-discrimination power parameter is the presence of obesity itself in the definition, either directly via BMI or indirectly via WC. It is easy to understand that, when BMI is used as part of the diagnosis, screening for the MS in obese children could show high prevalence; however, even when WC replaces BMI, prevalence remains high, owing to the use of a WC cutoff value (75-90th percentile) that includes the great majority of obese children. 28 All these considerations affect the sensitivity and specificity of the diagnosis of the MS in obese children, and could result in false-positive diagnoses. 12 The need for a re-evaluation of the MS diagnostic criteria is also confirmed from the recent findings of Li et al., 73 who diagnosed the MS in approximately 16% of normal-weight children; previous studies have also found MS and/or insulin resistance in healthy normal weight adults. [38] [39] [40] 74 According to the WHO definition, 6 DM2 is included in the diagnostic criteria for the MS. From a preventive point of view, it is difficult for pediatricians to agree that the presence of an overt disease like DM2 could have a clinical value equivalent to HDL cholesterol reduction, as this definition argues. Different items of MS diagnosis and risk assessment probably have different importance in terms of outcome prediction. 12, 42 Therefore, it is not clear which three components are used to make the diagnosis and whether the combination of any three is equally predictive. At the same time, it is not clear which could be the management of a child with only two items and therefore without a MS diagnosis. Even a child with one item deriving from a family with strong history of CVD or severe hypertension could have a high-risk estimation. 12, 42 We strongly support the view that maximal preventive and therapeutic efforts will have to be used until individual future risk can be accurately achieved. If we want to estimate risk at the population level rather than at an individual level, it is necessary to use continuous rather than dichotomous variables. 10 
Minor concerns
The available data did not show a marked tracking of the MS for CVD risks either on short-and on long-term period 11, 72, 75 and the predicting value of MS clustering seems not higher than any single parameter.
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A consistent body of data about the pathogenetic role of systemic indices of 'low-grade inflammation' in co-morbidity is now available. 12, 13, 22, [77] [78] [79] [80] However, at the present time, they were not considered for the MS diagnosis.
Emerging data on elevated C-reactive protein in obese children 22, 81 suggest it is an early candidate index, but efforts should be pursued to fill the pathophysiological gap uncovered by insulin resistance in the evolution of MS. Moreover, the existence of an inflammatory process in childhood obesity has been recently confirmed. 82 In addition, a chronic liver damage, such as non-alcoholic steatohepatitis (NASH), could be taken into account for a complete individual risk estimation, based on the high NASH frequency in the pediatric obese population and on possible multiple interrelationships between NASH and MS risk factors. 83, 84 Lifestyle and environmental variables seem to correlate with risk of developing the MS (for example, passive and active tobacco smoke exposure, physical inactivity and alcohol consumption), and could potentially be investigated when a risk assessment for the MS has to be carried out in a child. 85, 86 Metabolic risk-factor clustering estimation
Medical science usually defines a syndrome as an 'aggregate of symptoms and signs associated with any morbid process, and constituting together the picture of the disease'. 12, 87 The specific signs and symptoms are usually caused by a unifying underlying pathology, and their combination confers a risk that is different from the sum of the parts. It is necessary to consider the term itself, the clear pathophysiology, the variables included and excluded, the values needed for making the diagnosis, and the different treatment possibilities. 12 Consequently, very recent reports discussed the possibility of discouraging the growing use of the term 'metabolic syndrome', in favor of considering and subsequently treating each component separately. 9, 11, 13, 14 Several authors have tried to give different names to the MS, adding components to improve the validity of the overall diagnosis, 13, 14, 16, 36 but these may simply be causing confusion in
Metabolic risk-factor clustering estimation in children P Brambilla et al daily clinical practice. 13, 14 In light of this background, and taking into account the major and minor concerns discussed above, we argue that pediatricians need to consider a novel approach to assessing obese children, and should not simply derive or adapt definitions from adults. Moreover, the available definitions in children 21, 22 do not consider the pathophysiological basis of the clustering of CVD risk-factors of metabolic origin. 21, 34 Although, progress is being made in understanding the complex gene-environment interaction and associated developmental origin of risk-factors clustering. 88, 89 Following the recent recommendation of Grundy 14 regarding metabolic risk-factor clustering in adults, we propose a new comprehensive approach for Metabolic Individual Risk-factor And Clustering Estimation (MIRACLE) in children and adolescents. Taking into account the pediatrician's role in preventing future diseases, 90 we need first to direct our efforts towards collecting data on all the plausible variables to provide us with an overall picture, and then to select those variables with solid evidence to substantiate their relevance. In Figure 1 , we outline a multilevel global approach to examining patients. In brief, the overall evaluation of the risk is based on the combination of a first level that is anamnestic, a second level that is based on the present evaluation, and a third level that is represented by the possible clinical outcomes or diseases. We need to investigate both the family and the individual's history (i.e. the past), to evaluate clinical and metabolic abnormalities (i.e. the present) and then to identify clinical outcomes (i.e. the future) that could appear if the clustering of the risk factors continues for a long period of time, but could also already be present. [91] [92] [93] [94] This three-level evaluation is not considered as a 'chronological' evolution (i.e., step by step). Table 3 outlines our proposed components of the MIRACLE approach, together with suggested estimation methods and possible risk criteria, based on the available literature. Clearly, it is not simple to define and to quantify each item, and some suggested risk criteria reference standards are still missing, but this pathway could help pediatricians to decide which subjects to evaluate and follow-up in depth. In this scenario, we consider hypertension, recently confirmed a frequent finding in childhood obesity, [95] [96] as a clinical feature because of its possibility to be assessed during a standard clinical examination.
In Table 4 we consider only those components for which there is strong enough evidence for a clear definition. For family history, we have included the presence of early CVD, DM2 and hypertension. We have not included a family history of obesity, because there is no general agreement as to whether this factor adds an independent risk for CVD in addition to the presence of obesity in the subject. Family dyslipoproteinemia was not considered because obesityrelated dyslipidemia (i.e., high triglycerides and low HDLcholesterol levels) is not usually assessed by the general practitioner and because dyslipoproteinemia is a risk-factor and not a clinical outcome or a disease (unlike CVD, DM2 or hypertension). Family and individual lifestyle as well as infant feeding can be assessed, but there are no defined criteria to characterize unhealthy patterns. Socioeconomic status can also be assessed using different indicators and the most widely accepted is parental education level. However, the relationship between paternal education and CVD risk factors has not been adequately established, and there is also a potential risk of stigmatizing the family and the child. Adiposity rebound plays a major role in the development of obesity, but it remains to be clarified whether it has an independent role in the development of CVD. We did not include individual obesity history because it is difficult to estimate the exact date of appearance and therefore the duration of obesity. The presence of striae, common in adolescent obesity, is also difficult to assess objectively.
There is no consensus on age-, gender-and ethnic-groupspecific cutoffs for WC related to morbidity in children, but some standard references are now available in different populations. 52, [102] [103] [104] [105] Figure 2 compares the 90th WC centile in boys (Figure 2a ) and girls (Figure 2b ), and shows a difference between children from the US (i.e., EuropeanAmerican), UK, Spain, Canada and Australia. This difference is mainly related to the higher prevalence of obesity in North American than in European children. 106 Other factors, such as measurement procedures, year of data collection and sample size, could also affect the prevalence. As WC is an accurate estimate of abdominal adiposity, 107 and the available European standard references do not adequately detect its excess, we propose the use of the US 90th percentile to increase sensitivity. Some recent papers suggested that WC is an independent predictor of insulin resistance and CVD risk factors. 28, 108, 109 However, we strongly recommend carrying out more research to define the optimal WC values to detect an excess of abdominal adiposity in children.
Among the items that we do not consider in Table 4 , insulin and lipid exclusion need justification. We acknowledge that insulin resistance is a key factor associated with long-term obesity-related co-morbidities. 66 However, the
Multi-level approach to the overall Metabolic Individual Risk-factor And CLustering Estimation (MIRACLE)
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Metabolic risk-factor clustering estimation in children P Brambilla et al euglycemic hyperinsulinemic clamp, the golden standard for insulin resistance detection, cannot be used in pediatric clinical settings. Elevated fasting plasma insulin levels are considered a surrogate of insulin resistance but, at the present time, there are neither standardized assays available nor age-, maturation-, gender-and ethnic-specific reference values. The same could be applied for triglycerides and HDL-cholesterol serum levels. Moreover, the cutoff points used to identify abnormal lipid profiles have limited ability to predict children or adolescents who will have high-risk lipoprotein levels as adults. 53, 57 Recently, abnormal lipid thresholds have become available for 12-19-year-old adolescents 110 as indirectly linked to health risk, but they need to be validated with longitudinal studies. In addition, even low-density lipoprotein (LDL) cholesterol, which was recently related to cardiovascular risk-factors and showed longterm tracking power, should be included as parameter to measure. 42, 111, 112 When new research fills these knowledge gaps, insulin and lipid-profile parameters, which we believe are both potential factors to consider, could be included as components for evaluation. Returning to evidence-based items and looking at clinical management of such a list (Table 4) , we can determine the presence or the absence of each factor in the individual. One could argue that a global score could help to define better the subject's risk, and propose to assign a value of 1 to 'presence', and a value of 0 to 'absence'. Moreover, a separation of the family and individual history score from the clinical and metabolic score is possible, to distinguish potential factors from the already expressed ones. If a score was to be created, it could consider the 10 evidence-based items that quantify MIRACLE. Having at least half of these items 'positive' (or Metabolic risk-factor clustering estimation in children P Brambilla et al present) could mean that the subject needs very careful follow-up and evaluation over time. However, we strongly discourage calculating a score, because the identical value given to any item does not represent its real weight on CVD risk development. In addition, no published data could support different strategies based on the score. Nevertheless, this approach drives the pediatrician to an overall evaluation of the subject, by giving a fundamental value to anamnesis and physical examination. For future steps, it is fundamental to test the usefulness of such criteria to assess long-term cardiovascular outcomes or diseases in large longitudinal surveys.
Conclusion
In this paper, we carefully analyzed, in a clinical manner, the different criteria used in available pediatric studies to diagnose the MS. The great majority of pediatricians adopted criteria proposed for adults, and there were no reliable definitions of the MS in children. We presented our major and minor concerns regarding the use of existing definitions of the MS in children and adolescents. We also discussed the importance of considering factors derived from family and individual history, as well as from physical examination, in addition to metabolic risk-factor clustering. Finally, we proposed new potential items that should be considered in children and adolescents. The main outcome of this exercise has been 10 evidence-based items from which we could quantify the MIRACLE (see Table 4 ). We are aware that this is 52 UK, 102 Spain, 103 Australia 104 and Canada 105 boys (a) and girls (b) according to age.
Metabolic risk-factor clustering estimation in children P Brambilla et al just a step towards developing final estimation criteria; however, we hypothesize that this new approach would improve the overall quality of evaluation in children, it could optimize the use of the limited resources available to combat the obesity epidemic, and ultimately it may help to classify the risk of developing CVD in obese subjects. The pediatrician periodically needs to re-evaluate the growing subject, as the overall risk estimation could rapidly change. In addition, both normal-weight and overweight children and adolescents could be checked using this approach, as metabolic risk-factor clustering is not only peculiar in obese subjects. This complex approach to the subject requires time availability and more specific attention, but in the long-term these qualities could play a major role in health perspectives of the subject.
